Eli Lilly is scheduled to release its next earnings report on October 29, 2026, with consensus estimates calling for earnings of $9.83 per share, a 40.03% increase from the same quarter a year earlier, and revenue of $22.14 billion, up 25.77% year over year. For the full year, the Zacks Consensus Estimates forecast earnings of $36.66 per share and revenue of $88.94 billion, changes of +51.43% and +36.46% respectively compared to the previous year. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.86% higher, and Eli Lilly is currently a Zacks Rank #3 (Hold). The stock carries a Forward P/E ratio of 31.18, a premium to the industry average Forward P/E of 15.89, and a PEG ratio of 1.4 versus an average PEG ratio of 1.86 for the Large Cap Pharmaceuticals group. In the latest close session, Eli Lilly rose 1.26% to $1,157.49, outpacing the S&P 500's daily gain of 0.58%, while the Dow rose 0.49% and the Nasdaq gained 0.45%.
Eli Lilly and CompanyEli Lilly is set to report October 29 earnings with consensus EPS up 40% and revenue up 25.8% year over year, a financial/earnings event.
